Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camidanlumab tesirine - ADC Therapeutics/Genmab

Drug Profile

Camidanlumab tesirine - ADC Therapeutics/Genmab

Alternative Names: ADCT-301; Cami; HuMax®-TAC-ADC

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADC Therapeutics; Genmab
  • Developer ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Cell death stimulants; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Hodgkin's disease; Myelodysplastic syndromes; Myeloproliferative disorders
  • Phase I Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 24 May 2023 ADC Therapeutics terminates a phase II trial in Acute myeloid leukaemia, Myelodysplastic syndromes and Myeloproliferative disorders (Second-line therapy or greater, In adults, In the elderly) in USA (IV) due to reallocation of all resources to the phase III program (NCT04639024)
  • 28 Feb 2023 Camidanlumab tesirine - ADC Therapeutics/Genmab is available for licensing as of 06 Mar 2023. https://www.adctherapeutics.com/
  • 19 Jan 2023 ADC Therapeutics completes phase II trial for Hodgkin's disease (Second-line therapy or greater, In adolescents, In adults, In the elderly) in US, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, UK (IV) (NCT04052997) (EudraCT2018-002556-32)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top